Harvard Bioscience, Inc. (NASDAQ:HBIO) Sees Significant Growth in Short Interest

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 673,000 shares, an increase of 5.7% from the March 31st total of 636,700 shares. Based on an average trading volume of 86,900 shares, the days-to-cover ratio is presently 7.7 days.

Institutional Investors Weigh In On Harvard Bioscience

Large investors have recently modified their holdings of the stock. Bailard Inc. purchased a new stake in shares of Harvard Bioscience during the 4th quarter worth approximately $106,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Harvard Bioscience during the 3rd quarter valued at $124,000. Corsair Capital Management L.P. purchased a new position in shares of Harvard Bioscience during the 4th quarter valued at $356,000. BNP Paribas Financial Markets grew its position in shares of Harvard Bioscience by 38.7% during the 1st quarter. BNP Paribas Financial Markets now owns 75,970 shares of the medical instruments supplier’s stock valued at $322,000 after purchasing an additional 21,183 shares in the last quarter. Finally, WINTON GROUP Ltd grew its position in shares of Harvard Bioscience by 140.8% during the 3rd quarter. WINTON GROUP Ltd now owns 87,765 shares of the medical instruments supplier’s stock valued at $377,000 after purchasing an additional 51,316 shares in the last quarter. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Stock Performance

NASDAQ:HBIO opened at $3.82 on Thursday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.92 and a current ratio of 1.85. The firm has a market cap of $165.79 million, a price-to-earnings ratio of -47.74 and a beta of 1.42. Harvard Bioscience has a 52 week low of $3.44 and a 52 week high of $6.29. The firm has a 50-day moving average price of $4.19 and a two-hundred day moving average price of $4.46.

Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings data on Thursday, March 7th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $28.15 million during the quarter, compared to analysts’ expectations of $27.80 million. Harvard Bioscience had a negative net margin of 3.04% and a positive return on equity of 2.75%. On average, equities analysts expect that Harvard Bioscience will post 0.14 earnings per share for the current fiscal year.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.